

Cancer Vaccines

Manipulating Tumour Immunogenicity to be addressed at Cancer Vaccines Summit | 18-19 September, London UK

LONDON, UNITED KINGDOM, July 31, 2013 /EINPresswire.com/ -- New Speaker Announcement:

SMi are pleased to announce that Dr Mark Cobbold, Senior Clinical Research Fellow at the University of Birmingham, will be presenting at the 2nd annual <u>Cancer</u> <u>Vaccines</u> conference this September.

Attendees at this year's event will receive a unique insight into manipulating tumour immunogenicity. The presentation on: Manipulating Tumour Immunogenicity in vivo: New Tools for Old Targets, will highlight the following area's:



- New technology to alter the immunogenicity of a tumour in vivo.
- Manipulation by the delivery of antigens at the tumour site.
- The engagement of pre-existing immunity with tumours novel mechanism for immunotherapy

"

I am pleased to be taking part in Cancer Vaccines, which will highlight important advances both from the academic and industry viewpoints."

Prof. Graham Pawelec, University of Tübingen

Analogous to effective conjugate vaccines

Click here for full speaker line up.

An ideal platform for learning about the new advances in cancer vaccines, the 2nd annual event will present attendees with latest developments and innovations in this ever changing field.

Key Benefits of Attending:

- Explore T cell receptor mediated cytotoxicity in cancer cell lines with a detailed presentation from Christoph Lampert, Roche.
- Evaluate key regulatory issues from a keynote address with Alex Kudrin, Medical Assessor, Biological Licensing, MHRA

- Participate in the interactive pre-conference workshop on Combination Therapies with Immunotherapeutics led by Transgene
- Hear about the most advanced Phase III trials in Lung Cancer
- Consider the potential long term implications of inducing an anti-tumour immune response

Cancer Vaccines | 18-19 September, London UK
For further details visit the event website at www.cancervaccinesevent.com

Teri Arri SMi Group +44 (0)20 7827 6162 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/161229343

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.